Monday, August 12, 2013

US Big Biological Products and Medical Equipment & Instruments Corps 2Q 2013 Earnings Up 5%

I found 10 US Big Biological Products and Medical Equipment & Instruments Corps which generated After-tax Adjusted Earnings of more than $250 mil in either the 2Q 2013 or the 2Q 2012.

These 10 Corps generated Total Adjusted Earnings growth of 5% in the 2Q 2013 over the 2Q 2012.

This 5% total earnings growth in the 2Q 2013 is very misleading in real terms.  Most of these 10 Biological Products and Medical Equipment & Instruments Corps make continuing heavy investments in Research and Development.  US GAAP requires these R&D expenditures to be immediately charged to earnings, even though in the aggregate, these R&D expenditures reap substantial future earnings for many years, due to the related long patent lives.

In the 2Q 2013, the total R&D Expenditures of these 10 Corps were $3,418 mil, which was 51% of the $6,708 mil of Total Adjusted Earnings.  The two major R&D investment spenders in the 2Q 2013 were Amgen which invested $967 mil in R&D, up 17% over the 2Q 2012; and Gilead Sciences, which invested $524 mil in R&D, up 32% over the 2Q 2012.

Especially after factoring in the impact of the key R&D investments made, these 10 Biological Products and Medical Equipment & Instruments Corps did very well in real earnings' terms in the 2Q 2013.

When I put this altogether, I have to conclude that the Affordable Care Act has been extremely beneficial economically to all of the above 10 Biological Products and Medical Equipment & Instruments Corps.  And this very positive impact will continue far into the future.

Below here are the adjusted earnings of these 10 Corps for the 2Q 2013 and for the comparable 2Q 2012:
 

2Q 2013 2Q 2012


Adjusted Adjusted

Net Net

Income Income

From From

Continuing Continuing Increase Increase

Operations Operations (Decrease) (Decrease)

mil $s mil $s Amount %
Biological Products and Medical Equipment & Instruments Corps






Amgen                 1,444                 1,433                       11 1%
Medtronic                 1,124                 1,036                       88 8%
Gilead Sciences                     840                     767                       73 10%
Abbott Labs                     724                     689                       35 5%
Baxter                     639                     619                       20 3%
Biogen                     549                     439                     110 25%
Covidien Ltd                     427                     443                     (16) -4%
Stryker                     380                     375                         5 1%
Becton Dickinson                     306                     312                       (6) -2%
St Jude Medical                     275                     276                       (1) 0%





Total all 10                 6,708                 6,389                     319 5%